“disease control rate of 50% across a broad spectrum of solid...

“disease control rate of 50% across a broad spectrum of solid tumor types in a phase 1 dose escalation trial is an amazing result and validation of the groundbreaking science being developed by Imugene.”


HArry, As you said “amazing result”. There are two factors to consider here. Firstly this is a Ph1 trial. And it is showing that patients need healthy stem cell diversity. That’s the reason we are doing a ph1 trial. To collect this important data.

Yuman FONG said “CF33 works in all cancers!” He did not say “ it works in all patients “. So we now know that CF33 works best as a first line of therapy. Whilst the current patients have failed on 2,3 or even 4 lines of therapy, their immune system has been severely suppressed by these previous highly toxic therapies. There has also been cancer progression over this period. Further suppressing their immune system.

The other factor is as you pointed out , many patients started at suboptimal doses . The first patients started at a mouse dose.

Thats why LC is over the moon with excitement about “outstanding data”. Or “ we are collecting cancer data unlike anywhere else in the world “.

IMU will design further trials, with all of this knowledge in mind. This trial will give them the evidence needed to convince the FDA, that CF33 should be a first line of treatment. Because that’s what Ph1 trials do. They profuce the data requied to design the ph2 trials , that will enable progression to market.

Whilst many here may be unimpressed, LC is clearly very impressed. It’s worth remembering who the cancer trial expert is in this discussion.

The centrepiece of this trial is the fact that CF33 turns Cold Tumors to Hot Tumors.

That’s why LC is again pointing to the number of companies racing to get a foot hold in the CarT cellular therapy space. Because they will all want CF33 as an adjunct to their CarT therapies..

The first presentation of ONCARLYTICS will be on June 2 at ASCO . This is the last piece of the puzzle., If that data is good we are on our way to becoming the new SOC for cancer., IMU will take first prize in the race to beat cancer.,

Both Solid and Liquid tumors , 100% of the cancer market is ours. Between Azer-cel and CF33 we’ve got it covered.